gsk-1070806
mAbexperimental
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jan 5, 2010 (NCT01035645)
Timeline
Indications
Mechanism of action
- Interleukin-18INHIBITOR
IL18 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109606 ↗
Also known as
- gsk1070806
- gsk1070806
- gsk-1070806
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06447506 | Phase 2 | Jun 5, 2024 | GlaxoSmithKline |
| NCT05999799 | Phase 2 | Nov 15, 2023 | GlaxoSmithKline |
| NCT05590338 | Phase 1 | Oct 31, 2022 | GlaxoSmithKline |
| NCT04975438 | Phase 1 | Nov 10, 2021 | GlaxoSmithKline |
| NCT03681067 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | GlaxoSmithKline, University of Birmingham |
| NCT03522662 | Phase 2 | Aug 1, 2018 | University of Cambridge |
| NCT02723786 | Phase 2 | Aug 27, 2016 | GlaxoSmithKline |
| NCT01648153 | Phase 2 | Aug 1, 2012 | GlaxoSmithKline |
| NCT01035645 | Phase 1 | Jan 5, 2010 | GlaxoSmithKline |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 8 | 7 | 2 | 2010 |
| University of Birmingham | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Cambridge | Academic/Hospital | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1